Moderna being added to S&P 500
Moderna is on track to deliver 3 billion COVID-19 vaccines by 2022
Moderna chairman on dangers of COVID delta variant
Noubar Afeyan discusses the potential of a coronavirus booster shot on 'The Claman Countdown'
Moderna, one of the leading COVID-19 vaccine providers, is set to join the S&P 500, the broadest measure of the U.S. stock market at the close of trading Wednesday.
Shares have advanced over 280% during the past 12 months.
| Ticker | Security | Last | Change | Change % |
|---|---|---|---|---|
| MRNA | MODERNA INC. | 38.25 | +1.31 | +3.55% |
The inclusion may require mutual fund investors that mirror the benchmark to buy the stock which can often drive further gains.
RETAIL SALES SURGE AS ECONOMY GAINS MOMENTUM
The biotech company, which has already delivered over 100 million COVID-19 vaccines, will replace Alexion Pharmaceuticals Inc., which is being acquired by AstraZeneca on July 21 according to S&P Dow Jones Indices.
CLICK HERE TO READ MORE ON FOX BUSINESS
| Ticker | Security | Last | Change | Change % |
|---|---|---|---|---|
| ALXN | NO DATA AVAILABLE | - | - | - |
| AZN | ASTRAZENECA PLC | 64.26 | +1.06 | +1.68% |
GET FOX BUSINESS ON THE GO BY CLICKING HERE
Moderna is on track to deliver 1 billion COVID-19 vaccine doses this year and is aiming to increase that number by 2022 to up to 3 billion doses.
The U.S. has had more than 34.1 million confirmed COVID-19 cases and more than 609,000 deaths.
To date over 161.4 million Americans, 48.6% of the population, have been fully vaccinated and the Biden Administration is pushing more communities to get the dose.
This story, originally published on July 16, has been updated.